Tore K. Kvien

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 375 publications

Understanding patient-reported disease burden in systemic sclerosis: key clinical and demographic features revealed by the EULAR Systemic Sclerosis Impact of Disease (ScleroID) Questionnaire.

Understanding patient-reported disease burden in systemic sclerosis: key clinical and demographic features revealed by the EULAR Systemic Sclerosis Impact of Disease (ScleroID) Questionnaire.

Journal: EULAR rheumatology open

Published: August 01, 2026

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Journal: The Journal of rheumatology

Published: June 15, 2026

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Journal: The Journal of rheumatology

Published: June 15, 2026

Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries.

Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries.

Journal: Annals of the rheumatic diseases

Published: February 11, 2026

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration.

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 20, 2025

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.

Journal: Seminars in arthritis and rheumatism

Published: October 02, 2025

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial.

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial.

Journal: RMD open

Published: September 08, 2025

Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug-Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population.

Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug-Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population.

Journal: The Journal of rheumatology

Published: August 06, 2025

NSAID Use, Gastrointestinal Complications, and Burden of Disease in Osteoarthritis: Nordic Registry Study with Emphasis on Patients Below 60 Years.

NSAID Use, Gastrointestinal Complications, and Burden of Disease in Osteoarthritis: Nordic Registry Study with Emphasis on Patients Below 60 Years.

Journal: Rheumatology and therapy

Published: July 16, 2025

Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings.

Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: May 05, 2025

Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis.

Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis.

Journal: ACR open rheumatology

Published: April 17, 2025

Development of machine learning models for predicting non-remission in early RA highlights the robust predictive importance of the RAID score-evidence from the ARCTIC study.

Development of machine learning models for predicting non-remission in early RA highlights the robust predictive importance of the RAID score-evidence from the ARCTIC study.

Journal: Frontiers in medicine

Published: November 20, 2024

Showing 1-12 of 375

Last Updated: 09/26/2026